Phase 3 Completed N=39 Randomized Triple-blind Treatment

Therapies for Treatment-Resistant Panic Disorder Symptoms

Source: ClinicalTrials.gov NCT00118417 ↗

Enrolled (actual)

Serious AEs

6.1%

Results posted

Jul 2009

Primary outcomePrimary: Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6) — 4.3 Points on a scale — p=0.0000

Summary

This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Panic Disorder Symptoms, Phase 1 (Week 0 - Week 6)	4.3	0.0000 sig
PRIMARY Change in Panic Disorder Symptoms, Phase 2 (Week 6 - Week 12)	2.36; 2.31	0.97
PRIMARY Change in Panic Disorder Symptoms, Phase 3 (Week 12 - Week 24)	3.78; 2.9	0.061

Eligibility Criteria

Inclusion Criteria

Diagnosis of panic disorder

Exclusion Criteria

History of bipolar disorder, schizophrenia, psychosis, or delusional disorders
Post-traumatic stress disorder diagnosis within 6 months prior to study entry
Current use of psychotropic medications
Current use of cognitive behavioral therapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00118417). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.